Results 11 to 20 of about 7,924 (192)

Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers [PDF]

Human Vaccines & Immunotherapeutics, 2022
The CoronaVac vaccine was found to be effective against symptomatic COVID-19 and protective against severe disease in phase 3 studies. However, there are little data about its effectiveness in real-world conditions.
Gulsum Iclal Bayhan, Rahmet Guner
doaj   +5 more sources

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers [PDF]

Human Vaccines & Immunotherapeutics, 2023
The evidence on the waning protection of COVID-19 vaccines has been reviewed by the World Health Organization and has led to consideration of the need for booster doses.
Hazal Cansu Çulpan, Sümeyye Nur Aydın, Abdulkerim Uygur, Uğurcan Sayılı, Erkam Şeker, İ̇lker İnanç Balkan, Rıdvan Karaali, Beyhan Budak, Yılmaz Keskindemirci, Neşe Saltoğlu, Günay Can   +10 more
doaj   +6 more sources

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia [PDF]

Scientific Reports, 2022
Several vaccines have been fast-tracked through clinical trials to mitigate the progression of the SARS‑CoV‑2 pandemic. We analyzed sequential blood samples from 314 recipients of Comirnaty and CoronaVac in East Malaysia for the spike-binding IgG (IgG-S),
Cheng Siang Tan, Vaenessa Noni, Whilemena Upam Herman Ulok Melina, Ummi Syafiqah Abdorahman, Joseph Niler Bimbang, Natasya Marliana Abdul Malik, Mohammad Esa Hossen, Md Mizanur Rahman, Lela Su’ut, Asri Said, Claire Chen, Bego Sepop, Morni Abu Samat, John Chee Ming Chew, Dewi Mamora, Sian Kong Tan   +15 more
doaj   +5 more sources

CoronaVac vaccine does not affect ovarian reserve [PDF]

Ginekologia Polska, 2023
In this study, our aim is to investigate the effect of CoronaVac vaccine on ovarian reserve in female patients followed up for infertility.Our study is a retrospective study. Forty-six infertile patients who received two doses of CoronaVac vaccine one month apart and had not had a previous Covid 19 infection were included in the study.
Ayşe Rabia, Şenkaya, Zafer, Çil, Ömür, Keskin, Mehmet Emin, Güneş, Deniz, Can Öztekin   +4 more
core   +6 more sources

Immunogenicity after CoronaVac vaccination [PDF]

Revista da Associação Médica Brasileira, 2021
This study aimed to investigate the seropositivity of CoronaVac-SinoVac vaccination in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) risk factors and comorbidities.Immunoglobulin (IgG) antibody responses were examined on the 21st day after the second dose of CoronaVac-SinoVac 6 μg vaccine on the 28th day.
Eda Çelik Güzel, Aliye Çelikkol, Berna Erdal, Nuriye Sedef   +3 more
openaire   +8 more sources

Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study [PDF]

COVID, 2022
The ongoing COVID-19 pandemic remained a major public health concern despite a large-scale deployment of vaccines. One of the vaccines is CoronaVac, an inactivated vaccine. The efficacy of the vaccine was estimated at 50.7–83.5% in clinical trials. However, the real-world efficacy often differed.
Sri Masyeni, Edison Johar, Anak Agung Gede Budhitresna, Nyoman Mahardika, Nyoman Ratna Kartika Dewi, I Gde Raka Widiana, Frilasita Aisyah Yudhaputri, Khin Saw Aye Myint   +7 more
openaire   +2 more sources

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil [PDF]

Nature Medicine, 2022
AbstractThere is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of
Cerqueira-Silva, T, Katikireddi, SV, de Araujo Oliveira, V, Flores-Ortiz, R, Júnior, JB, Paixão, ES, Robertson, C, Penna, GO, Werneck, GL, Barreto, ML, Pearce, N, Sheikh, A, Barral-Netto, M, Boaventura, VS   +13 more
openaire   +11 more sources

Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort [PDF]

Vaccines, 2022
The CoronaVac vaccine is the most used anti-SARS-CoV-2 vaccine worldwide. Previous data indicate that this vaccine produces a lower immune response than RNA vaccines such as BNT162b2.
Rene Clavero, Alfredo Parra-Lucares, Gabriel Méndez-Valdés, Eduardo Villa, Karin Bravo, Evelyn Mondaca, Josseline Aranda, Rose Brignardello, Cynthia Gajardo, Angelica Ordenes, Evelyn Colombo, Jessica Tapia, Andoni Etcheverry, José Zúñiga, Luis Toro   +14 more
doaj   +3 more sources

Humoral Immune Response to CoronaVac in Turkish Adults [PDF]

Vaccines, 2023
While most approved vaccines are based on the viral spike protein or its immunogenic regions, inactivated whole-virion vaccines (e.g., CoronaVac) contain additional antigens that may enhance protection. This study analyzes short-term humoral responses against the SARS-CoV-2 spike (S1) and nucleocapsid (NCP) protein in 50 Turkish adults without previous
Yasemin Cosgun, Nergis Emanet, Ayten Öz Kamiloglu, Evelin Grage-Griebenow, Susann Hohensee, Sandra Saschenbrecker, Katja Steinhagen, Gulay Korukluoglu   +7 more
openaire   +4 more sources

Sobre a eficácia da CoronaVac no Twitter: conversações e aspectos políticos

Liinc em Revista, 2022
A CoronaVac, desenvolvida no Brasil pelo Instituto Butantan em parceria com a Sinovac, manteve-se em meio às disputas políticas que permearam o modo como o nosso país enfrentou a pandemia da COVID-19. Com o objetivo de mapear e compreender, em um período
Carina Luisa Ochi Flexor, Gustavo Costa, Vitória Lobo Batista Barros   +2 more
doaj   +2 more sources